Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 15, 2010The Journal of Clinical Endocrinology & Metabolism

Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience

View Full Paper
Ask AI
Bookmark
Share

Authors

MCMaria E. CabanillasThe University of Texas MD Anderson Cancer CenterSWSteven G. WaguespackThe University of Texas MD Anderson Cancer CenterYBYulia BronsteinMinnesota Public Radio

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cabanillas et al. (2010) studied this question.

synapsesocial.com/papers/6a95cabd0becc3d96d376a53https://doi.org/10.1210/jc.2009-1923
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis2007 · 299 citations
  2. 2Phase II Trial of Sorafenib in Advanced Thyroid Cancer2008 · 681 citations
  3. 3Influence of the BRAF V600E Mutation on Expression of Vascular Endothelial Growth Factor in Papillary Thyroid Cancer2006 · 157 citations
  4. 4Serum Vascular Endothelial Growth Factor Levels Are Elevated in Metastatic Differentiated Thyroid Cancer but Not Increased by Short-Term TSH Stimulation2002 · 87 citations